MX2025011286A - Formulaciones vacunales basadas en proteinas meningococicas y metodos para su fabricacion - Google Patents

Formulaciones vacunales basadas en proteinas meningococicas y metodos para su fabricacion

Info

Publication number
MX2025011286A
MX2025011286A MX2025011286A MX2025011286A MX2025011286A MX 2025011286 A MX2025011286 A MX 2025011286A MX 2025011286 A MX2025011286 A MX 2025011286A MX 2025011286 A MX2025011286 A MX 2025011286A MX 2025011286 A MX2025011286 A MX 2025011286A
Authority
MX
Mexico
Prior art keywords
manufacturing
methods
fusion proteins
vaccine formulations
protein based
Prior art date
Application number
MX2025011286A
Other languages
English (en)
Spanish (es)
Inventor
Sambhaji Shankar Pisal
Dattatreya Sarma Annamraju
Rajeev Mhalasakant Dhere
Original Assignee
Serum Institute Of India Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serum Institute Of India Pvt Ltd filed Critical Serum Institute Of India Pvt Ltd
Publication of MX2025011286A publication Critical patent/MX2025011286A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/095Neisseria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55544Bacterial toxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MX2025011286A 2023-03-24 2025-09-24 Formulaciones vacunales basadas en proteinas meningococicas y metodos para su fabricacion MX2025011286A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202321021121A IN202321021121A (https=) 2023-03-24 2023-03-24
PCT/IN2024/050300 WO2024201502A1 (en) 2023-03-24 2024-03-22 Meningococcal protein based vaccine formulations and methods for manufacturing thereof

Publications (1)

Publication Number Publication Date
MX2025011286A true MX2025011286A (es) 2025-11-03

Family

ID=92903953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025011286A MX2025011286A (es) 2023-03-24 2025-09-24 Formulaciones vacunales basadas en proteinas meningococicas y metodos para su fabricacion

Country Status (12)

Country Link
EP (1) EP4687967A1 (https=)
JP (1) JP2026511179A (https=)
KR (1) KR20250166279A (https=)
CN (1) CN121038809A (https=)
AR (1) AR132199A1 (https=)
AU (1) AU2024249503A1 (https=)
IL (1) IL323559A (https=)
IN (1) IN202321021121A (https=)
MX (1) MX2025011286A (https=)
TW (1) TW202444740A (https=)
UY (1) UY40678A (https=)
WO (1) WO2024201502A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025224732A1 (en) * 2024-04-26 2025-10-30 Techinvention Lifecare Private Limited Meningococcal hexavalent combination vaccine
CN119925588B (zh) * 2025-04-08 2025-07-01 北京华诺泰生物医药科技有限公司 基于gE/pORF7双抗原纳米晶与智能相变佐剂的重组带状疱疹疫苗
CN120227449A (zh) * 2025-05-21 2025-07-01 苏州聚微生物科技有限公司 B群脑膜炎球菌疫苗组合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596240B (zh) * 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
EP2970920B1 (en) * 2013-03-15 2018-04-25 The Children's Hospital of Philadelphia Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
CN110804102B (zh) * 2019-11-08 2021-07-20 苏州微超生物科技有限公司 B群脑膜炎球菌疫苗及其制备方法与应用

Also Published As

Publication number Publication date
AR132199A1 (es) 2025-06-04
JP2026511179A (ja) 2026-04-10
CN121038809A (zh) 2025-11-28
KR20250166279A (ko) 2025-11-27
WO2024201502A1 (en) 2024-10-03
TW202444740A (zh) 2024-11-16
IN202321021121A (https=) 2024-04-19
IL323559A (en) 2025-11-01
AU2024249503A1 (en) 2025-10-16
EP4687967A1 (en) 2026-02-11
UY40678A (es) 2024-10-15

Similar Documents

Publication Publication Date Title
MX2025011286A (es) Formulaciones vacunales basadas en proteinas meningococicas y metodos para su fabricacion
WO2021216743A3 (en) Coronavirus vaccines, compositions, and methods related thereto
WO2021154812A8 (en) Coronavirus vaccine formulations
WO2007024941A3 (en) Polyvalent vaccine
WO2021243122A3 (en) Engineered coronavirus spike (s) protein and methods of use thereof
DE602005015990D1 (de) Immunogene t-helfer epitope von menschlichen tumorantigenen und deren verwendung in immunotherapeutischen methoden
WO2006081007A3 (en) Use of flagellin in tumor immunotherapy
WO2010019262A3 (en) Polyvalent vaccine
EP2181714A3 (en) Immunogenic composition for use in vaccination against staphylococcei
WO2007092792A3 (en) Yeast-based vaccine for inducing an immune response
PL1635863T3 (pl) Kompozycje do wywoływania, wzmacniania i utrzymywania odpowiedzi immunologicznych na epitopy ograniczone do MHC klasy I do celów profilaktycznych i leczniczych
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
IL138075A0 (en) Vaccines, immunotherapeutics and methods for using the same
DE602006019446D1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
PT1897555E (pt) Vacina omv suplementada contra meningococos
WO2006046978A3 (en) Cationic peptide-mediated transformation
WO2023102448A3 (en) Coronavirus vaccine formulations
WO2010120874A3 (en) Chimeric therapeutics, compositions, and methods for using same
WO2008118487A3 (en) Compositions and methods for incresing immunogenicity of glycoprotein vaccines
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
MX2023009728A (es) Vacuna recombinante meningococica b.
AU2002319501A1 (en) Materials and methods relating to improved vaccination strategies
DK1726215T3 (da) Fremgangsmåde til fremstilling af soja og mælkebaserede præparater med et höjt samlet proteinindhold
AU2003255275A1 (en) Improved anthrax vaccines and delivery methods
MX2025013140A (es) Composiciones para el uso en el tratamiento del acne